Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what remains.

Newron Pharmaceuticals S.p.A. (SIX:NWRN; Xetra:NP5) fell CHF4.45 (71%) to CHF1.80 on Monday after the Italian specialty pharma said sarizotan missed the primary and secondary endpoints in the Phase II/III STARS trial to treat Rett syndrome patients...